Pharmacologic inhibition of PARP is the primary therapeutic strategy for BReast CAncer gene (BRCA) mutant ovarian cancer, but most patients carry wild-type BRCA1/2 and show no clinical benefits from PARP inhibitors [72,73]. Here, PARP1 is linked to ovarian carcinoma.